| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2009PNAS..10614138S |
| P356 | DOI | 10.1073/PNAS.0906467106 |
| P932 | PMC publication ID | 2729033 |
| P698 | PubMed publication ID | 19666557 |
| P5875 | ResearchGate publication ID | 26728435 |
| P50 | author | Fernando Queiroz Cunha | Q38330464 |
| Erna G. Kroon | Q40456670 | ||
| Mauro M Teixeira | Q43261431 | ||
| P2093 | author name string | Danielle G Souza | |
| Caio T Fagundes | |||
| Daniela Sachs | |||
| Flavio A Amaral | |||
| Alena Atrasheuskaya | |||
| Eugenij Bukin | |||
| George Ignatyev | |||
| Adriano L Souza | |||
| Lirlandia P Sousa | |||
| Rafael S Souza | |||
| P2860 | cites work | Dengue: defining protective versus pathologic immunity | Q24609884 |
| Leukocyte-dependent histamine release from rabbit platelets. The role of IgE, basophils, and a platelet-activating factor | Q24679152 | ||
| New mouse model for dengue virus vaccine testing | Q27469339 | ||
| Study of Dengue virus infection in SCID mice engrafted with human K562 cells. | Q27469587 | ||
| Dengue: an escalating problem | Q27469692 | ||
| Dengue Fever in Humanized NOD/SCID Mice | Q27472676 | ||
| Murine Model for Dengue Virus-Induced Lethal Disease with Increased Vascular Permeability | Q27477548 | ||
| Pharmacological actions of PCA 4248, a new platelet-activating factor receptor antagonist: in vivo studies | Q28330691 | ||
| Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis | Q28345121 | ||
| Platelet-activating factor (PAF) receptor and genetically engineered PAF receptor mutant mice | Q28609411 | ||
| Development of a novel mouse model for dengue virus infection | Q33330448 | ||
| Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection | Q33346586 | ||
| A cascade of cytokines mediates mechanical inflammatory hypernociception in mice. | Q33819799 | ||
| Platelet-activating factor, a pleiotrophic mediator of physiological and pathological processes | Q35621992 | ||
| Rodent models for the study of therapy against flavivirus infections | Q35867772 | ||
| Impaired anaphylactic responses with intact sensitivity to endotoxin in mice lacking a platelet-activating factor receptor | Q36400935 | ||
| Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical | Q36510607 | ||
| Wild dengue virus types 1, 2 and 3 viremia in rhesus monkeys | Q39011713 | ||
| Characterization of a dengue patient cohort in Recife, Brazil. | Q40430488 | ||
| Natural history of dengue virus (DENV)-1 and DENV-4 infections: reanalysis of classic studies. | Q40456663 | ||
| Early clinical and laboratory indicators of acute dengue illness | Q40647872 | ||
| A higher production of platelet activating factor in ex vivo heterologously secondary dengue-2 virus infections | Q40690200 | ||
| Role of PAF receptors during intestinal ischemia and reperfusion injury. A comparative study between PAF receptor-deficient mice and PAF receptor antagonist treatment | Q41886673 | ||
| Inhibition by CV-3988 of the binding of [3H]-platelet activating factor (PAF) to the platelet | Q42204871 | ||
| Proinflammatory gene induction by platelet-activating factor mediated via its cognate nuclear receptor | Q44223906 | ||
| UK-74,505, a novel and selective PAF antagonist, exhibits potent and long lasting activity in vivo | Q46753689 | ||
| Dengue: defining protective versus pathologic immunity | Q56793103 | ||
| Experimental Trypanosoma cruzi infection in platelet-activating factor receptor-deficient mice | Q57034251 | ||
| Platelet activating factor receptor-deficient mice present delayed interferon-γ upregulation and high susceptibility to Leishmania amazonensis infection | Q58857645 | ||
| A lethal role of platelet activating factor in anaphylactic shock in mice | Q70363804 | ||
| Effect of a novel potent platelet-activating factor antagonist, modipafant, in clinical asthma | Q72204971 | ||
| Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309: a prospective, multicenter, double-blind, randomized phase II trial. TCV-309 Septic Shock Study Group | Q73117996 | ||
| Signaling via platelet-activating factor receptors accounts for the impairment of neutrophil migration in polymicrobial sepsis | Q79834671 | ||
| P433 | issue | 33 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pathogenesis | Q372016 |
| Dengue virus | Q476209 | ||
| modulation by virus of host process | Q14818042 | ||
| P304 | page(s) | 14138-43 | |
| P577 | publication date | 2009-08-18 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Essential role of platelet-activating factor receptor in the pathogenesis of Dengue virus infection | |
| P478 | volume | 106 |
| Q35235639 | A detrimental role for invariant natural killer T cells in the pathogenesis of experimental dengue virus infection |
| Q27305445 | A model of DENV-3 infection that recapitulates severe disease and highlights the importance of IFN-γ in host resistance to infection |
| Q51745540 | A preliminary study on efficacy of rupatadine for the treatment of acute dengue infection. |
| Q59360236 | An Industry Perspective on Dengue Drug Discovery and Development |
| Q37987131 | Animal models of dengue virus infection |
| Q36061451 | CCAAT/enhancer-binding protein δ facilitates bacterial dissemination during pneumococcal pneumonia in a platelet-activating factor receptor-dependent manner |
| Q30430891 | Complement C5 activation during influenza A infection in mice contributes to neutrophil recruitment and lung injury |
| Q92988061 | Contemporary Strategies and Current Trends in Designing Antiviral Drugs against Dengue Fever via Targeting Host-Based Approaches |
| Q36280060 | Dengue Virus-Induced Inflammation of the Endothelium and the Potential Roles of Sphingosine Kinase-1 and MicroRNAs. |
| Q34367194 | Dengue vaccines: recent developments, ongoing challenges and current candidates |
| Q38158411 | Dengue virus infection: current concepts in immune mechanisms and lessons from murine models |
| Q26700116 | Dengue virus requires the CC-chemokine receptor CCR5 for replication and infection development |
| Q33623803 | Detection of driver metabolites in the human liver metabolic network using structural controllability analysis. |
| Q30842619 | Development of a model of Saint Louis encephalitis infection and disease in mice |
| Q36859054 | Development of a transmission model for dengue virus |
| Q37123259 | Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection |
| Q27305770 | IFN-γ production depends on IL-12 and IL-18 combined action and mediates host resistance to dengue virus infection in a nitric oxide-dependent manner |
| Q39034933 | IL-22 modulates IL-17A production and controls inflammation and tissue damage in experimental dengue infection |
| Q37901360 | Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms |
| Q39309253 | In vivo infection by a neuroinvasive neurovirulent dengue virus |
| Q33387265 | Induction of shock after intravenous injection of adenovirus vectors: a critical role for platelet-activating factor |
| Q94587197 | Inflammatory signaling in dengue-infected platelets requires translation and secretion of nonstructural protein 1 |
| Q57177662 | Innovation and trends in the development and approval of antiviral medicines: 1987-2017 and beyond |
| Q94502693 | Integrative Proteome and Acetylome Analyses of Murine Responses to Cryptococcus neoformans Infection |
| Q59354754 | Interleukin-33 contributes to disease severity in Dengue virus infection in mice |
| Q40331473 | Intracerebral infection with dengue-3 virus induces meningoencephalitis and behavioral changes that precede lethality in mice |
| Q54438632 | Lack of platelet-activating factor receptor protects mice against diet-induced adipose inflammation and insulin-resistance despite fat pad expansion. |
| Q62485312 | Metabolomic Insights into Human Arboviral Infections: Dengue, Chikungunya, and Zika Viruses |
| Q41929865 | Metabolomics analyses identify platelet activating factors and heme breakdown products as Lassa fever biomarkers |
| Q40236877 | Nitric oxide synthase expression correlates with death in an experimental mouse model of dengue with CNS involvement |
| Q39258872 | Pathogenesis of vascular leak in dengue virus infection |
| Q39756120 | Platelet Activating Factor (PAF) Receptor Deletion or Antagonism Attenuates Severe HSV-1 Meningoencephalitis |
| Q35043739 | Platelet activating factor contributes to vascular leak in acute dengue infection |
| Q38614021 | Platelet-activating factor increases reactive oxygen species-mediated microbicidal activity of human macrophages infected with Leishmania (Viannia) braziliensis |
| Q39100666 | Platelet-activating factor receptor blockade ameliorates Aggregatibacter actinomycetemcomitans-induced periodontal disease in mice |
| Q27312687 | Platelet-activating factor receptor plays a role in lung injury and death caused by Influenza A in mice |
| Q55004062 | Platelets in Immune Response to Virus and Immunopathology of Viral Infections. |
| Q36992653 | Re-evaluation of the pathogenic roles of nonstructural protein 1 and its antibodies during dengue virus infection |
| Q33393510 | Role of the chemokine receptors CCR1, CCR2 and CCR4 in the pathogenesis of experimental dengue infection in mice |
| Q38013700 | Sphingosine kinase 1 in viral infections. |
| Q90737186 | Structure-Based Design of Antivirals against Envelope Glycoprotein of Dengue Virus |
| Q33414560 | Subversion of early innate antiviral responses during antibody-dependent enhancement of Dengue virus infection induces severe disease in immunocompetent mice |
| Q37611829 | Targeting host factors to treat West Nile and dengue viral infections |
| Q38071254 | Targeting the "cytokine storm" for therapeutic benefit |
| Q90401541 | The Era of Thromboinflammation: Platelets Are Dynamic Sensors and Effector Cells During Infectious Diseases |
| Q27693180 | The platelet activating factor (PAF) signaling cascade in systemic inflammatory responses |
| Q56378131 | The role of lipids in the inception, maintenance and complications of dengue virus infection |
| Q21245298 | Viral hemorrhagic fevers: advancing the level of treatment |
| Q64122039 | WIPO Re:Search: Catalyzing Public-Private Partnerships to Accelerate Tropical Disease Drug Discovery and Development |
| Q38674884 | Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? Questions Raised by the Development and Implementation of Dengue Vaccines: Example of the Sanofi Pasteur Tetravalent Dengue Vac |
Search more.